Accumulating evidence has suggested that inhibition of HGF/c-Met signaling could serve as a useful therapeutic strategy for attenuating the growth and metastasis of various human cancers, including HCC, colorectal cancer, lung cancer, head and neck cancer, cervical cancer, etc. [39]. This evidence concerns the gene HGF and hepatocellular carcinoma.